CDMO Avara To Acquire Novartis’ Sterile Mfg Facility, Development CenterBy
Avara Pharmaceutical Services, a Norwalk, Connecticut-headquartered contract development and manufacturing organization, has agreed to acquire Novartis’ sterile manufacturing facility for injectable medicines in Canada.
The proposed acquisition of Novartis Technical Operations’ sterile manufacturing facility and the adjacent Sandoz Development Center located on the Sandoz Canada campus in Boucherville, Quebec, is expected to be finalized in the next few months, following the completion of a number of closing conditions, including receipt of antitrust approvals, according to Avara.
As part of the asset-purchase agreement, the parties have agreed to sign a long-term supply contract to guarantee continuous supply of products manufactured in Boucherville. Avara says it does not anticipate any impact on jobs and intends to invest in the site and pursue business-development opportunities to improve the plant’s use and expand its customer base.
This move follows Avara’s recent acquisitions of a sterile manufacturing facility from Pfizer in Liscate, Italy and of a solid-dose manufacturing facility from GlaxoSmithKline in Aiken, South Carolina. It will bring the number of manufacturing and development sites operated by Avara worldwide to ten: two in Canada; four in the US, including corporate headquarters and one facility in Puerto Rico; one in the UK; one in Ireland; one in Italy; and one in France.
Source: Avara Pharmaceutical Services